BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protein found in human gastric juice. It has been the subject of extensive preclinical research spanning over two decades, with studies examining its effects on tissue repair across virtually every organ system.
The compound is notable for its stability — unlike many peptides, BPC-157 demonstrates resistance to enzymatic degradation and does not require a carrier protein for activity. This stability profile is unusual for a peptide of its size and has contributed to its extensive study across multiple administration routes.
Research interest centers on its ability to accelerate healing in tendons, ligaments, muscle, bone, the gastrointestinal tract, and even neural tissue in animal models.
Research Applications
Published preclinical research has examined BPC-157 in the following contexts:
- Musculoskeletal repair: Tendon-to-bone healing, Achilles tendon transection, quadriceps muscle crush injuries, and ligament reconstruction models
- Gastrointestinal protection: NSAID-induced lesions, inflammatory bowel disease models, esophageal and gastric damage, fistula healing
- Vascular effects: Vessel-to-vessel anastomosis, thrombosis prevention, blood pressure regulation in various models
- Neurological: Peripheral nerve transection repair, traumatic brain injury models, dopaminergic system modulation
- Organ protection: Liver damage (alcohol-induced, NSAID-induced), pancreatic lesions, cardiac damage models
Dosage Information (Research Use)
Published research protocols in animal models have used a wide dosage range depending on the specific model being studied. The following represents doses documented in published literature, scaled for reference purposes:
- Standard research range: 200-800 mcg/day (subcutaneous administration in rodent models, allometrically scaled)
- Common protocol duration: 4-12 weeks in most published studies
- Administration frequency: Once or twice daily in most protocols
- Routes studied: Subcutaneous, intraperitoneal, intragastric, topical, and oral
Note: These reflect published research protocols in animal models. No standardized human dosing exists. This compound is sold for research purposes only.
Reconstitution & Handling
Reconstitute lyophilized BPC-157 with bacteriostatic water (BAC water) for research use:
- Use a sterile alcohol swab to clean both the peptide vial stopper and the BAC water vial
- Draw the desired volume of BAC water into a sterile syringe
- Inject BAC water slowly down the inside wall of the peptide vial — do not spray directly onto the powder
- Gently swirl until fully dissolved (do not shake)
- Store reconstituted solution at 2-8°C and use within 30 days
Example: 5mg vial + 2mL BAC water = 2,500 mcg/mL concentration. For a 250 mcg dose, draw 10 units on a standard insulin syringe.
Use the PeptideBible Reconstitution Calculator for precise measurements.
Half-Life & Pharmacokinetics
The half-life of BPC-157 has not been precisely established in published pharmacokinetic studies. Based on its stability profile and observed duration of effect in research models, estimated activity duration is approximately 24 hours following subcutaneous administration, supporting once-daily dosing protocols seen in most published research.
Reported Observations in Literature
Published preclinical literature reports a favorable safety profile across numerous studies:
- No reported organ toxicity in chronic administration studies in rodent models
- No observed mutagenic or carcinogenic effects in available data
- LD50 has not been established — no lethal dose found in toxicology screening
- Some in vitro research has examined effects on cell proliferation pathways, warranting monitoring in relevant research contexts
No human safety data from controlled clinical trials exists.
Key Research References
- Sikiric P, et al. “Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.” Curr Neuropharmacol. 2016
- Chang CH, et al. “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” J Appl Physiol. 2011
- Seiwerth S, et al. “BPC 157 and Standard Angiogenic Growth Factors.” Curr Pharm Des. 2018
- Sikiric P, et al. “Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract.” Curr Pharm Des. 2011